MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Vivani Medical

Затворен

1.01 1

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.98

Максимум

1.01

Ключови измерители

By Trading Economics

Служители

36

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+292.16% upside

Дивиденти

By Dow Jones

Следващи печалби

9.05.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

61M

Предишно отваряне

0.01

Предишно затваряне

1.01

Vivani Medical Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

13.06.2024 г., 15:28 ч. UTC

Значими двигатели на пазара

Vivani Medical Shares Up, FDA Cleared New Drug Application to Start Diabetes Trial

Сравнение с други в отрасъла

Ценова промяна

Vivani Medical Прогноза

Ценова цел

By TipRanks

292.16% нагоре

12-месечна прогноза

Среден 4 USD  292.16%

Висок 4 USD

Нисък 4 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Vivani Medical през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

2

Купи

0

Задържане

0

Продай

Финанси

$

Относно Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.